As generic companies win the third trial surrounding the method-of-use patent of Novartis’ ‘Entresto,’ a heart failure treatment, they are one step closer to an early entry of their generic products.

Now, the patent hurdle is down to two for early entry of generic versions of Entresto. If generic companies succeed in overcoming the remaining two patents, an annual market size of KRW 60 billion is anticipated to open.

On April 8, the pharmaceutical industry reported that the Supreme Court ruled of ‘discontinuance of a trial’ on Novartis’ appeal against Hanmi Pharmaceutical and others in Entresto’s method-of-use patent nullification trial.

The ‘discontinuanc